ZNTL
$2.73
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a P...
Recent News
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon
Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC), emphasizing a targeted approach in patients with high cyclin E1 protein expression. Speaking at a Guggenhe
Mitsui Sumitomo Continues to Build WR Berkley Stake
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well.
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying
Zentalis Pharmaceuticals (ZNTL) has come into focus after progress in its azenosertib oncology program, including completed enrollment in the Phase 2 DENALI trial, FDA alignment on the Phase 3 ASPENOVA design, and a large insider share purchase. See our latest analysis for Zentalis Pharmaceuticals. The latest clinical milestones and insider buying have coincided with a sharp shift in sentiment, with a 7 day share price return of 172.99% and a 90 day share price return of 130.86%. However, the...
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners
Key Insights Institutions' substantial holdings in Zentalis Pharmaceuticals implies that they have significant...
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...